Abstract
Discontinuation or poor adherence to antipsychotics in patients with schizophrenia may lead to relapses. Compared with daily administered antipsychotics (e.g., paliperidone extended-release (ER)), long-acting injectable antipsychotics (LAI) can improve medication adherence, resulting in a lower risk of relapse. Paliperidone palmitate, a new form of LAI, can be administered monthly (PP1M), three monthly (PP3M), or six-monthly (PP6M). While proven effective in improving compliance, the economic value of administering this high-cost treatment is unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
